FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4319461549> ?p ?o ?g. }

• W4319461549 endingPage "12" @default.
• W4319461549 startingPage "1" @default.
• W4319461549 abstract "ABSTRACTBackground Supplementation with Angiotensin-(1-7) [(Ang-1-7)] has received considerable attention due to its possible ergogenic effects on physical performance. The effects of a single dose of Ang-(1-7) on the performance of mountain bike (MTB) athletes during progressive load tests performed until the onset of voluntary fatigue have previously been demonstrated. This study tested the effects of Ang-(1-7) in two different exercise protocols with different metabolic demands: aerobic (time trial) and anaerobic (repeated sprint).Methods Twenty one male recreational athletes were given capsules containing an oral formulation of HPβCD-Ang-(1-7) (0.8 mg) and HPβCD-placebo (only HPβCD) over a 7-day interval; a double-blind randomized crossover design was used. Physical performance was examined using two protocols: a 20-km cycling time trial or 4 × 30-s repeated all-out sprints on a leg cycle ergometer. Data were collected before and after physical tests to assess fatigue parameters, and included lactate levels, and muscle activation during the sprint protocol as evaluated by electromyography (EMG); cardiovascular parameters: diastolic and systolic blood pressure and heart rate; and performance parameters, time to complete (time trial), maximum power and mean power (repeated sprint).Results Supplementation with an oral formulation of HPβCD-Ang-(1-7) reduced basal plasma lactate levels and promoted the maintenance of plasma glucose levels after repeated sprints. Supplementation with HPβCD-Ang-(1-7) also increased baseline plasma nitrite levels and reduced resting diastolic blood pressure in a time trial protocol. HPβCD-Ang-(1-7) had no effect on the time trial or repeat sprint performance, or on the EMG recordings of the vastus lateralis and vastus medialis.Conclusions Supplementation with HPβCD-Ang-(1-7) did not improve physical performance in time trial or in repeated sprints; however, it promoted the maintenance of plasma glucose and lactate levels after the sprint protocol and at rest, respectively. In addition, HPβCD-Ang-(1-7) also increased resting plasma nitrite levels and reduced diastolic blood pressure in the time trial protocol.Trial registration RBR-2nbmpbc, registered January 6th, 2023. The study was prospectively registered.KEYWORDS: Angiotensin-(1-7)exerciseperformancenutritionmountain biketime trial 20 km and repeat sprint AcknowledgmentsThe authors would like to sincerely thank the participants for volunteered participating in this study and to the Laboratory of Clinical Analysis Pilot (LAPAC) of the School of Pharmacy/Federal University of Ouro Preto for the biochemical dosages.Authors’ contributionsSSM and FADMJ were responsible for data collection, data interpretation, writing and revision of the manuscript, under the guidance and assistance of LKB, DMS and RASS who assisted in each stage and finalization of the manuscript. ECO and DBC assisted in the revision of the manuscript. DB and AELS data analysis and interpretation. The authors declare that there is no conflict of interest with the current publication, and all authors have approved the final version of the manuscript.Disclosure statementNo potential conflict of interest was reported by the authors.Availability of data and materialsThe datasets generated and/or analyzed as part of the current study are not publicly available due to confidentiality agreements with participants. However, they can be made available solely for the purpose of review and not for the purpose of publication from the corresponding author upon reasonable request.Ethics approval and consent to participateThis study was approved by the Ethics Committee on Human Research of the Federal University of Ouro Preto (protocol number:14,912,519.4.0000.5150). All procedures followed the Brazilian guidelines and standards for human research. Participants were informed about the research objectives, the steps to be taken, and the risks and benefits of their participation. Those who agreed to participate signed an informed consent form. Trial registration: RBR-2nbmpbc, registered January 6th, 2023. The study was prospectively registered.Consent for publicationNot applicable, no individual person’s data was presented.Supplementary materialSupplemental data for this article can be accessed online at https://doi.org/10.1080/00913847.2023.2175587Additional informationFundingPró-Reitoria de Pesquisa, Pós-Graduação e Inovação (PROPPI-UFOP) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), financing of inputs (kit of reagents). Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) funding scholarships. The agencies did not play any role in the design of the study and in the collection, analysis and interpretation of data and in the writing of the manuscript." @default.
• W4319461549 created "2023-02-09" @default.
• W4319461549 creator A5007636308 @default.
• W4319461549 creator A5012504132 @default.
• W4319461549 creator A5031687019 @default.
• W4319461549 creator A5049069211 @default.
• W4319461549 creator A5050771168 @default.
• W4319461549 creator A5064383058 @default.
• W4319461549 creator A5074883957 @default.
• W4319461549 creator A5076965286 @default.
• W4319461549 creator A5090651911 @default.
• W4319461549 date "2023-02-20" @default.
• W4319461549 modified "2023-10-07" @default.
• W4319461549 title "Effects of oral HPΒCD-angiotensin-(1-7) supplementation on recreational mountain bike athletes: a crossover study" @default.
• W4319461549 cites W1682254341 @default.
• W4319461549 cites W1821554906 @default.
• W4319461549 cites W1965026439 @default.
• W4319461549 cites W1997201589 @default.
• W4319461549 cites W2000439420 @default.
• W4319461549 cites W2021390874 @default.
• W4319461549 cites W2032651888 @default.
• W4319461549 cites W2034963012 @default.
• W4319461549 cites W2036732386 @default.
• W4319461549 cites W2038628089 @default.
• W4319461549 cites W2070119291 @default.
• W4319461549 cites W2084034472 @default.
• W4319461549 cites W2101576799 @default.
• W4319461549 cites W2117642435 @default.
• W4319461549 cites W2118535591 @default.
• W4319461549 cites W2126676515 @default.
• W4319461549 cites W2129670071 @default.
• W4319461549 cites W2136280068 @default.
• W4319461549 cites W2137070227 @default.
• W4319461549 cites W2160883624 @default.
• W4319461549 cites W2169630686 @default.
• W4319461549 cites W2328849045 @default.
• W4319461549 cites W2756220877 @default.
• W4319461549 cites W2895688181 @default.
• W4319461549 cites W2914853620 @default.
• W4319461549 cites W2967533411 @default.
• W4319461549 cites W2972088421 @default.
• W4319461549 cites W2977684219 @default.
• W4319461549 cites W2981394932 @default.
• W4319461549 cites W3009403915 @default.
• W4319461549 cites W3118412515 @default.
• W4319461549 cites W4299627282 @default.
• W4319461549 doi "https://doi.org/10.1080/00913847.2023.2175587" @default.
• W4319461549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36752064" @default.
• W4319461549 hasPublicationYear "2023" @default.
• W4319461549 type Work @default.
• W4319461549 citedByCount "1" @default.
• W4319461549 countsByYear W43194615492023 @default.
• W4319461549 crossrefType "journal-article" @default.
• W4319461549 hasAuthorship W4319461549A5007636308 @default.
• W4319461549 hasAuthorship W4319461549A5012504132 @default.
• W4319461549 hasAuthorship W4319461549A5031687019 @default.
• W4319461549 hasAuthorship W4319461549A5049069211 @default.
• W4319461549 hasAuthorship W4319461549A5050771168 @default.
• W4319461549 hasAuthorship W4319461549A5064383058 @default.
• W4319461549 hasAuthorship W4319461549A5074883957 @default.
• W4319461549 hasAuthorship W4319461549A5076965286 @default.
• W4319461549 hasAuthorship W4319461549A5090651911 @default.
• W4319461549 hasBestOaLocation W43194615492 @default.
• W4319461549 hasConcept C102959455 @default.
• W4319461549 hasConcept C105795698 @default.
• W4319461549 hasConcept C126322002 @default.
• W4319461549 hasConcept C142724271 @default.
• W4319461549 hasConcept C164705383 @default.
• W4319461549 hasConcept C1862650 @default.
• W4319461549 hasConcept C204787440 @default.
• W4319461549 hasConcept C27081682 @default.
• W4319461549 hasConcept C2776868573 @default.
• W4319461549 hasConcept C2777953023 @default.
• W4319461549 hasConcept C33923547 @default.
• W4319461549 hasConcept C5140985 @default.
• W4319461549 hasConcept C71924100 @default.
• W4319461549 hasConcept C84393581 @default.
• W4319461549 hasConcept C87813604 @default.
• W4319461549 hasConceptScore W4319461549C102959455 @default.
• W4319461549 hasConceptScore W4319461549C105795698 @default.
• W4319461549 hasConceptScore W4319461549C126322002 @default.
• W4319461549 hasConceptScore W4319461549C142724271 @default.
• W4319461549 hasConceptScore W4319461549C164705383 @default.
• W4319461549 hasConceptScore W4319461549C1862650 @default.
• W4319461549 hasConceptScore W4319461549C204787440 @default.
• W4319461549 hasConceptScore W4319461549C27081682 @default.
• W4319461549 hasConceptScore W4319461549C2776868573 @default.
• W4319461549 hasConceptScore W4319461549C2777953023 @default.
• W4319461549 hasConceptScore W4319461549C33923547 @default.
• W4319461549 hasConceptScore W4319461549C5140985 @default.
• W4319461549 hasConceptScore W4319461549C71924100 @default.
• W4319461549 hasConceptScore W4319461549C84393581 @default.
• W4319461549 hasConceptScore W4319461549C87813604 @default.
• W4319461549 hasFunder F4320321091 @default.
• W4319461549 hasFunder F4320322980 @default.
• W4319461549 hasLocation W43194615491 @default.
• W4319461549 hasLocation W43194615492 @default.
• W4319461549 hasLocation W43194615493 @default.

• next